Align Technology Inc (ALGN)
Healthcare
Medical Instruments & Supplies
169.20 $
Closing price · As of: 31. Jul 2026
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Align Technology Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 7 of our scanner strategies — each hit links to the scanner.
Growth
Quality & Balance Sheet
Momentum & Trend
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Basics
Market Cap
The value of the entire company on the market: share price times total shares outstanding.
12.5$B
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
72Mio.
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
93.6%
Beta
Volatility versus the overall market: 1 = moves like the market, 2 = twice as much, under 1 = calmer than the market.
1.7
Performance
Perf. 1M
Price performance over the last month.
0.10%
Perf. 3M
Price performance over the last 3 months.
4.20%
Perf. 6M
Price performance over the last 6 months.
9.90%
YTD Performance (%)
Price performance since the start of the year (Year to Date).
7.90%
52-Week-High Distance
How far the price sits below its highest point over the last 52 weeks. 0% means the stock is at its year high.
-15.7%
Valuation
P/E
Price-to-earnings ratio: how many years of profit does the stock cost? The lower, the cheaper the valuation. No earnings means no P/E.
28.9
Forward P/E
P/E based on expected earnings for the next 12 months instead of past earnings — analysts' bet on the future.
16.2
PEG
P/E divided by expected earnings growth: puts valuation in relation to growth. Around 1 is considered fair, well above that is pricey.
1.0
P/B
Price-to-book ratio: market value relative to book equity.
3.0
P/S
Price-to-sales ratio: market value divided by annual sales. Important for companies that aren't (yet) profitable.
3.1
EV/EBITDA
Enterprise value including debt (EV) relative to operating profit before depreciation and amortization (EBITDA) — more comparable than P/E because debt counts too. Extreme values arise when EBITDA is near zero.
14.0
Price/FCF
Market value divided by free cash flow: how many years of freely available cash does the stock cost? More honest than P/E because cash flow is harder to dress up.
18.2
Profitability
Gross Margin
Gross margin: what's left of sales after only direct production costs are deducted — the product's pricing power.
69.9%
EBIT Margin
EBIT margin: operating profit as a percentage of sales — the earning power of the core business before interest and taxes.
16.6%
Net Margin
Net margin: what's left of sales as profit after ALL costs, interest, and taxes.
10.5%
Return on Equity
Return on equity: how much profit does the company generate per year on shareholders' equity?
10.8%
Return on Assets
Return on assets: how much profit the company generates from its total assets (equity and debt combined).
7.2%
Balance Sheet & Safety
Equity Ratio
Equity ratio: equity as a share of total assets. The higher, the more resilient the balance sheet.
65.7%
Debt/Equity
Leverage ratio: financial debt divided by equity. Under 1 is generally seen as solid; negative values mean negative equity.
0.03
fortress balance sheet
Altman Z″
Edward Altman's bankruptcy early-warning score. We use the Z″ variant, built from four balance-sheet ratios — it is designed for service companies and non-manufacturers and uses book value instead of market value. On that scale: below 1.1 = danger zone, 2.6 and up = safe zone, in between a grey area. Because the classic Altman Z is calculated differently, the two numbers are not directly comparable. The formula does not fit banks, insurers, or real-estate stocks.
8.05
very solid
Piotroski
Balance-sheet health check by Joseph Piotroski: 9 yes/no criteria on profit, cash flow, leverage, and efficiency. 7+ is very solid, under 3 is a red flag.
9 out of 9
Growth
Sales Growth Last Quarter
Sales growth in the most recently reported quarter versus the same quarter a year ago (YoY).
6.20%
EPS Growth Last Quarter
Growth in earnings per share in the most recently reported quarter versus the same quarter a year ago (YoY).
23.90%
Sales Growth (Year)
Sales growth in the last fiscal year versus the year before.
0.90%
Forward Sales Growth
Sales growth analysts expect over the next 12 months — an estimate, not a guarantee.
4.40%
Forward EPS Growth
Earnings-per-share growth analysts expect over the next 12 months — an estimate, not a guarantee.
8.90%
Quality & Screener
Stage
Weinstein phases 1 through 4: 1 = basing, 2 = uptrend (the only buy phase), 3 = topping, 4 = downtrend. Measured against the 30-week line.
1
RS Rating
Relative strength from 1 to 99: an RS of 95 means the stock has outperformed 95% of all stocks.
37
EPS Rating
Earnings growth rating from 1 to 99 versus all stocks — high values mean above-average earnings growth.
68
very solid
Piotroski
Balance-sheet health check by Joseph Piotroski: 9 yes/no criteria on profit, cash flow, leverage, and efficiency. 7+ is very solid, under 3 is a red flag.
9 out of 9
Fundamental Rating
Our own Fundamental Rating: 0 to 100 points with an A+ to F grade. 50 points is the average across the universe, 100 the best possible score. It scores growth, earnings surprises, analyst estimates, margins, cash flow, and balance-sheet safety — every stock percentile-ranked against all others. Grades: A+ from 95, A from 75, B from 55, C from 45, D from 25, E from 5, F below.
B (59 out of 100)
fortress balance sheet
Altman Z″
Edward Altman's bankruptcy early-warning score. We use the Z″ variant, built from four balance-sheet ratios — it is designed for service companies and non-manufacturers and uses book value instead of market value. On that scale: below 1.1 = danger zone, 2.6 and up = safe zone, in between a grey area. Because the classic Altman Z is calculated differently, the two numbers are not directly comparable. The formula does not fit banks, insurers, or real-estate stocks.
8.05
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 1.39 | -14.80 | 995 | 4.00 | 10.40 | 286 | 263 |
| 2025: Q1 | 1.27 | -9.20 | 979 | -1.80 | 9.50 | 53 | 27 |
| 2025: Q2 | 1.72 | 33.70 | 1,012 | -1.60 | 12.30 | 129 | 154 |
| 2025: Q3 | 0.78 | -49.50 | 996 | 1.80 | 5.70 | 189 | 122 |
| 2025: Q4 | 1.89 | 35.70 | 1,048 | 5.30 | 13.00 | 223 | 290 |
| 2026: Q1 | 1.57 | 24.30 | 1,040 | 6.20 | 10.80 | 151 | 120 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
Align Technology, Inc. bietet Invisalign-Klaraligner, Vivera-Retainer und iTero-Intraoralscanner und -dienste in den USA, der Schweiz und international an.
| CEO Insider Trades (12 Mo.) | buying own stock |
|---|---|
| Employees | 20,275 |
| Headquarters | Tempe, AZ |
| Website | aligntech.com |
| IPO Date | 26. Jan 2001 |
| Next Earnings | 29. Jul 2026 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Joseph M. Hogan | President, CEO & Director | 1957 |
| John F. Morici | CFO & Executive VP of Global Finance | 1967 |
| Julie Ann Coletti J.D. | Executive VP and Chief Legal & Regulatory Officer | 1968 |
| Zelko Relic | Executive VP & CTO | 1965 |
| Shirley Stacy | Vice President of Corporate Communications & Investor Relations | – |
| Richardson Jaime Holte | Executive Vice President of Global Human Resources | – |
| Sreelakshmi Kolli | Executive VP and Chief Product & Digital Officer | 1975 |
| Srini Kaza | Executive Vice President of Research & Development | – |
| Mitra Derakhshan | Executive VP, Chief Clinical Officer, Global Treatment Planning & Clinical Services | – |
| David Carr | Executive VP and MD of EMEA | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.